Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7511688 | 0.87 | POLB (0.61) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL688492 | 0.84 | POLB (1.00) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL15082379 | 0.83 | POLB (0.79) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL6869171 | 0.77 | POLB (0.50) | POLBMAPTSMN1; SMN2HTTKMT2A | |
| Glycerin SCHEMBL3843204 | 0.77 | POLB (0.83) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL14477946 | 0.76 | POLB (0.73) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL8293964 | 0.75 | POLB (0.67) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL29265031 | 0.75 | POLB (0.67) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL5499784 | 0.75 | POLB (0.66) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL7951946 | 0.75 | POLB (0.66) | POLBMAPTSMN1; SMN2HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-1265862-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | POLB 1239/4885MAPT 957/4885SMN1; SMN2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.